0001567619-21-022000.txt : 20211214 0001567619-21-022000.hdr.sgml : 20211214 20211214125821 ACCESSION NUMBER: 0001567619-21-022000 CONFORMED SUBMISSION TYPE: D PUBLIC DOCUMENT COUNT: 1 ITEM INFORMATION: 06b FILED AS OF DATE: 20211214 DATE AS OF CHANGE: 20211214 EFFECTIVENESS DATE: 20211214 FILER: COMPANY DATA: COMPANY CONFORMED NAME: NERVGEN PHARMA CORP. CENTRAL INDEX KEY: 0001751912 IRS NUMBER: 000000000 STATE OF INCORPORATION: A1 FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: D SEC ACT: 1933 Act SEC FILE NUMBER: 021-424846 FILM NUMBER: 211490310 BUSINESS ADDRESS: STREET 1: SUITE 1703 - 595 BURRARD STREET CITY: VANCOUVER STATE: A1 ZIP: V7X 1J1 BUSINESS PHONE: 6047225361 MAIL ADDRESS: STREET 1: SUITE 1703 - 595 BURRARD STREET CITY: VANCOUVER STATE: A1 ZIP: V7X 1J1 D 1 primary_doc.xml X0708 D LIVE 0001751912 NERVGEN PHARMA CORP. SUITE 1703 - 595 BURRARD STREET VANCOUVER A1 BRITISH COLUMBIA, CANADA V7X 1J1 (604) 488-5421 BRITISH COLUMBIA, CANADA None None Corporation true 2017 Bill Radvak Suite 1703 - 595 Burrard Street Vancouver A1 BRITISH COLUMBIA, CANADA V7X 1J1 Director Brian Bayley Suite 1703 - 595 Burrard Street Vancouver A1 BRITISH COLUMBIA, CANADA V7X 1J1 Director Michael Abrams Suite 1703 - 595 Burrard Street Vanouver A1 BRITISH COLUMBIA, CANADA V7X 1J1 Director Harold Punnett Suite 1703 - 595 Burrard Street Vancouver A1 BRITISH COLUMBIA, CANADA V7X 1J1 Director Paul Brennan Suite 1703 - 595 Burrard Street Vancouver A1 BRITISH COLUMBIA, CANADA V7X 1J1 Director Executive Officer Randall Kaye Suite 1703 - 595 Burrard Street Vancouver A1 BRITISH COLUMBIA, CANADA V7X 1J1 Director William Adams Suite 1703 - 595 Burrard Street Vancouver A1 BRITISH COLUMBIA, CANADA V7X 1J1 Executive Officer Daniel Mikol Suite 1703 - 595 Burrard Street Vancouver A1 BRITISH COLUMBIA, CANADA V7X 1J1 Executive Officer Glenn Ives Suite 1703 - 595 Burrard Street Vancouver A1 BRITISH COLUMBIA, CANADA V7X 1J1 Director Krista McKerracher Suite 1703 - 595 Burrard Street Vancouver A1 BRITISH COLUMBIA, CANADA V7X 1J1 Director Other Decline to Disclose 06b false 2021-11-29 true true true true Units consist of one common share and one-half common share purchase warrant, each whole warrant exercisable at CAD$3.20 per share until November 29, 2023. false 0 1052930 651815 401115 Total amount remaining to be sold represents the maximum potential exercise price of warrants. Subscriptions paid in Canadian currency converted to US dollars at CAD$1.2621= USD$1.00. false 17 0 0 0 false NERVGEN PHARMA CORP. /s/ William Adams William Adams CFO 2021-12-08